Jedd Wolchok
Jedd Wolchok
Chief, Melanoma and Immunotherapeutics, MSKCC
Verified email at - Homepage
Cited by
Cited by
Improved survival with ipilimumab in patients with metastatic melanoma
FS Hodi, SJ O'day, DF McDermott, RW Weber, JA Sosman, JB Haanen, ...
New England Journal of Medicine 363 (8), 711-723, 2010
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ...
Science 348 (6230), 124-128, 2015
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
C Robert, L Thomas, I Bondarenko, S O'Day, J Weber, C Garbe, C Lebbe, ...
New England Journal of Medicine 364 (26), 2517-2526, 2011
Nivolumab plus ipilimumab in advanced melanoma
JD Wolchok, H Kluger, MK Callahan, MA Postow, NA Rizvi, AM Lesokhin, ...
N Engl J Med 369, 122-133, 2013
Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ...
New England Journal of Medicine 369 (2), 134-144, 2013
Genetic basis for clinical response to CTLA-4 blockade in melanoma
A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ...
New England Journal of Medicine 371 (23), 2189-2199, 2014
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
H Peinado, M Alečković, S Lavotshkin, I Matei, B Costa-Silva, ...
Nature medicine 18 (6), 883-891, 2012
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
JD Wolchok, A Hoos, S O'Day, JS Weber, O Hamid, C Lebbé, M Maio, ...
Clinical cancer research 15 (23), 7412-7420, 2009
Cancer immunotherapy using checkpoint blockade
A Ribas, JD Wolchok
Science 359 (6382), 1350-1355, 2018
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
MA Postow, J Chesney, AC Pavlick, C Robert, K Grossmann, ...
New England Journal of Medicine 372 (21), 2006-2017, 2015
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline
JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ...
Journal of clinical oncology: official journal of the American Society of …, 2018
Immune checkpoint blockade in cancer therapy
MA Postow, MK Callahan, JD Wolchok
Journal of clinical oncology 33 (17), 1974, 2015
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ...
Science 351 (6280), 1463-1469, 2016
Antibody therapy of cancer
AM Scott, JD Wolchok, LJ Old
Nature reviews cancer 12 (4), 278-287, 2012
Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
D Schadendorf, FS Hodi, C Robert, JS Weber, K Margolin, O Hamid, ...
Journal of clinical oncology 33 (17), 1889, 2015
Immunologic correlates of the abscopal effect in a patient with melanoma
MA Postow, MK Callahan, CA Barker, Y Yamada, J Yuan, S Kitano, Z Mu, ...
New England Journal of Medicine 366 (10), 925-931, 2012
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ...
The Lancet 384 (9948), 1109-1117, 2014
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
The system can't perform the operation now. Try again later.
Articles 1–20